The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first monobactam/β-lactamase inhibitor combination to be cleared in the US for ...

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

His early efforts were focused on monocyclic beta-lactam antibiotics, exemplified by the monobactam aztreonam, and culminated in the identification of a pre-clinical drug candidate, U-78608, a potent ...

and Monobactam. By drug origin, the market is categorized into natural, semisynthetic, and synthetic. By spectrum of activity, the market is bifurcated into broad-spectrum antibiotic and ...